📣 VC round data is live. Check it out!
- Public Comps
- New Horizon Health
New Horizon Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for New Horizon Health and similar public comparables like OPKO Health, Azenta, ToolGen, Novogene and more.
New Horizon Health Overview
About New Horizon Health
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
Founded
2018
HQ

Employees
878
Website
Financials (FY)
EV
$816M
Valuation Multiples
Start free trialNew Horizon Health Financials
New Horizon Health reported last fiscal year revenue of $112M and negative EBITDA of ($7M).
In the same fiscal year, New Horizon Health generated $95M in gross profit, ($7M) in EBITDA losses, and had net loss of ($12M).
New Horizon Health P&L
In the most recent fiscal year, New Horizon Health reported revenue of $112M and EBITDA of ($7M).
New Horizon Health is unprofitable as of last fiscal year, with gross margin of 84%, EBITDA margin of (6%), and net margin of (10%).
Financial data powered by Morningstar, Inc.
New Horizon Health Stock Performance
New Horizon Health has current market cap of $816M, and enterprise value of $816M.
New Horizon Health's stock price is $3.64.
New Horizon Health has an EPS (earnings per share) of $-0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $816M | $816M | 0.0% | — | — | — | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNew Horizon Health Valuation Multiples
New Horizon Health trades at 7.3x EV/Revenue multiple, and (120.8x) EV/EBITDA.
New Horizon Health Financial Valuation Multiples
As of May 10, 2026, New Horizon Health has market cap of $816M and EV of $816M.
New Horizon Health has a P/E ratio of (70.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified New Horizon Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


New Horizon Health Margins & Growth Rates
In the most recent fiscal year, New Horizon Health reported gross margin of 84%, EBITDA margin of (6%), and net margin of (10%).
New Horizon Health Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
New Horizon Health Operational KPIs
New Horizon Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
New Horizon Health Competitors
New Horizon Health competitors include OPKO Health, Azenta, ToolGen, Novogene, Personalis, Castle Biosciences, Abclon, Eckert & Ziegler, CareDx and Genfit.
Most New Horizon Health public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.5x | 1.6x | (22.0x) | (7.0x) | |||
| 0.9x | 0.9x | 8.5x | 9.0x | |||
| 798.1x | — | (30.8x) | — | |||
| 2.1x | 2.1x | 13.8x | 13.7x | |||
| 6.2x | 5.9x | (6.1x) | (4.9x) | |||
| 1.1x | 1.1x | 8.7x | 12.2x | |||
| 173.1x | — | (49.9x) | — | |||
| 2.8x | 2.8x | 9.2x | 9.5x | |||
This data is available for Pro users. Sign up to see all New Horizon Health competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout New Horizon Health
| When was New Horizon Health founded? | New Horizon Health was founded in 2018. |
| Where is New Horizon Health headquartered? | New Horizon Health is headquartered in China. |
| How many employees does New Horizon Health have? | As of today, New Horizon Health has over 878 employees. |
| Is New Horizon Health publicly listed? | Yes, New Horizon Health is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of New Horizon Health? | New Horizon Health trades under NHZHY ticker. |
| When did New Horizon Health go public? | New Horizon Health went public in 2021. |
| Who are competitors of New Horizon Health? | New Horizon Health main competitors include OPKO Health, Azenta, ToolGen, Novogene, Personalis, Castle Biosciences, Abclon, Eckert & Ziegler, CareDx, Genfit. |
| What is the current market cap of New Horizon Health? | New Horizon Health's current market cap is $816M. |
| What is the current revenue of New Horizon Health? | New Horizon Health's last fiscal year revenue is $112M. |
| What is the current EV/Revenue multiple of New Horizon Health? | Current revenue multiple of New Horizon Health is 7.3x. |
| Is New Horizon Health profitable? | No, New Horizon Health is not profitable. |
| How many companies New Horizon Health has acquired to date? | New Horizon Health hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies New Horizon Health has invested to date? | New Horizon Health hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to New Horizon Health
Lists including New Horizon Health
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.